COVID-19 drug lead treatments identified
- Details
- Category: Research
An international team of researchers has tested more than 10,000 compounds to identify six drug candidates that may help treat COVID-19.
The research, involving University of Queensland scientist Professor Luke Guddat, tested the efficacy of approved drugs, drug candidates in clinical trials and other compounds.
Potential harms of chloroquine, hydroxychloroquine and azithromycin for treating COVID-19
- Details
- Category: Research
Chloroquine, hydroxychloroquine and azithromycin are being used to treat and prevent COVID-19 despite weak evidence for effectiveness, and physicians and patients should be aware of the drugs' potentially serious adverse events, states a review in CMAJ (Canadian Medical Association Journal).
Lancaster academic sees positives in first published clinical trial of COVID-19 treatment
- Details
- Category: Research
A Lancaster University statistician who worked on the first published large randomised clinical trial for a potential treatment for the COVID-19 virus said the scientific community was coming together to combat the coronavirus. There are currently no specific treatments for COVID-19. However, it is possible that some existing drugs, usually used for other conditions, may have some benefits.
Trial drug can significantly block early stages of COVID-19 in engineered human tissues
- Details
- Category: Research
An international team led by University of British Columbia researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts. The findings, published in Cell, hold promise as a treatment capable of stopping early infection of the novel coronavirus.
Possible coronavirus drug identified by Australian scientists
- Details
- Category: Research
A collaborative study led by Monash University's Biomedicine Discovery Institute (BDI) in Melbourne, Australia, with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), has shown that an anti-parasitic drug already available around the world kills the virus within 48 hours.
Clues to COVID-19 coronavirus's vulnerability emerge from an antibody against SARS
- Details
- Category: Research
An antibody recovered from a survivor of the SARS epidemic in the early 2000s has revealed a potential vulnerability of the new coronavirus at the root of COVID-19, according to a study from scientists at Scripps Research.
The study, published today in Science, is the first to map a human antibody's interaction with the new coronavirus at near-atomic-scale resolution.
New guidelines on caring for ICU patients with COVID-19
- Details
- Category: Development
An international team including McMaster University researchers has come together to issue guidelines for health-care workers treating intensive care unit (ICU) patients with COVID-19. The Surviving Sepsis Campaign COVID-19 panel has released 54 recommendations on such topics as infection control, laboratory diagnosis and specimens, the dynamics of blood flow support, ventilation support, and COVID-19 therapy.
More Pharma News ...
- FDA approves first plasma therapy for Houston Methodist COVID-19 patient
- Experimental AI tool predicts which COVID-19 patients develop respiratory disease
- Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19)
- Singapore modelling study estimates impact of physical distancing on reducing spread of COVID-19
- CAR macrophages go beyond T cells to fight solid tumors
- Vivli to launch a portal for sharing data from COVID-19 trials
- Understanding how COVID-19 affects children vital to slowing pandemic